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neural stem cells (NSCs) results in the early
maturation of NSC derived
oligodendrocytes in vitro
Poommaree Namchaiw1, Han Wen1,4, Florian Mayrhofer1, Olga Chechneva1,3, Sangita Biswas1,2,3* and
Wenbin Deng1,3*
Abstract
Background: Oligodendrocytes are a type of glial cells that synthesize the myelin sheath around the axons and are
critical for the nerve conduction in the CNS. Oligodendrocyte death and defects are the leading causes of several
myelin disorders such as multiple sclerosis, progressive multifocal leukoencephalopathy, periventricular
leukomalacia, and several leukodystrophies. Temporal activation of the Sonic Hedgehog (SHH) pathway is critical for
the generation of oligodendrocyte progenitors, and their differentiation and maturation in the brain and spinal
cord during embryonic development in mammals.
Methods: Our protocol utilized adherent cultures of human induced pluripotent stem cells (iPSC) and human
embryonic stem cells (hESCs) with a green fluorescent protein (GFP) reporter knocked into one allele of the OLIG2
gene locus, dual SMAD inhibition, and transient partial inhibition of glioma-associated oncogene 1 (GLI1) by the
small molecule GANT61 during the formation of the SOX2/PAX6-positive neural stem cells (NSCs). The SHH
pathway was later restimulated by a Smoothened agonist purmorphamine to induce the generation of OLIG2 glial
precursors. One hundred ninety-two individual oligodendrocyte precursor cells (OPCs) from GANT61 and control
group were analyzed by single-cell RNA sequencing (RNA-Seq).
Results: We demonstrate here that transient and partial inhibition of the SHH pathway transcription factor GLI1 in
NSCs by a small molecule inhibitor GANT61 was found to generate OPCs that were more migratory and could
differentiate earlier toward myelin-producing oligodendrocytes. Single-cell transcriptomic analysis (RNA-Seq)
showed that GANT61-NSC-derived oligodendrocyte precursor cells (OPCs) had differential activation of some of the
genes in the cytoskeleton rearrangement pathways that are involved in OPC motility and induction of maturation.
At the protein level, this was also associated with higher levels of myelin-specific genes in the GANT61 group
compared to controls. GANT61-NSC-derived OPCs were functional and could generate compact myelin in vitro and
in vivo after transplantation in myelin-deficient shiverer mice.
Conclusions: This is a small molecule-based in vitro protocol that leads to the faster generation of functional
oligodendrocytes. The development of protocols that lead to efficient and faster differentiation of oligodendrocytes
from progenitors provides important advances toward the development of autologous neural stem cell-based
therapies using human iPSCs.
Keywords: Oligodendrocyte, GANT61, Myelination, NSC, Sonic Hedgehog, SHH, OPC, RNA-Seq, Differentiation, GLI1,
hiPSC, hESC, Small molecule
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Background
Oligodendrocytes (OLs) are a type of glial cells that are
essential for the generation of the myelin sheath around
the axonal processes in the mammalian central nervous
system [1, 2]. Myelin is critically important for nerve
conduction, axonal integrity and survival, and patho-
logical changes in the oligodendrocyte metabolism can
result in neurodegeneration. Before maturing into myeli-
nating oligodendrocytes, oligodendrocyte precursor cells
(OPCs) pass through multiple developmental stages,
which can be characterized by their specific morpholo-
gies and expression of various transcription factors and
cellular markers [1]. Activation of the Sonic Hedgehog
(SHH) pathway is critical for the generation of oligoden-
drocytes. During embryonic development, SHH is
secreted from the neural floor plate and forms a concen-
tration gradient along the ventral notochord resulting in
the switching of the ventral neural progenitor toward an
oligodendroglial progenitor fate [3]. The activation of
SHH signaling results in fate switching of neural stem cells
(NSCs) to neural/glial antigen 2 (NG2)+/OLIG2+ motor
neuron and OPCs [4–6]. Although the fundamental path-
ways of oligodendrocyte lineage commitment are highly
conserved between human and mouse, still they do not
fully recapitulate the timeline of human brain develop-
ment. For example, during human embryonic develop-
ment, gliogenesis begins at the second trimester and
extends into adulthood [7, 8] while in rodent, it begins
postnatally [8, 9]. Human induced pluripotent stem cell
(iPSC) technology, on the other hand, allows us to com-
plement our knowledge on human oligodendroglial devel-
opment [10, 11]. Specifically, NSCs generated from
human induced pluripotent stem cells (hiPSCs) and hu-
man embryonic stem cells (hESCs) have provided valuable
mechanistic insights into the critical genes, transcription
factors, morphogens, and regulatory elements that are
activated during the generation of oligodendrocytes and
subsequently their differentiation and myelination. iPSC-
derived NSCs can be patterned in vitro toward a ventral
spinal cord glial progenitor fate and driven to differentiate
toward myelinating oligodendrocytes mainly through the
activation of the SHH signaling pathways [12–14]. Specif-
ically, the stimulation of SHH signaling activates its down-
stream effectors smoothened (SMO) and the glioma-
associated oncogene homolog (GLI) family of zinc finger
transcription factors that target several genes critical for
oligodendrocyte specification and development [4, 15–19].
Previously, continuous stimulation of the SHH signaling
pathway through either the Patch receptors or Smooth-
ened receptors was used in most oligodendroglial differen-
tiation protocols including our laboratory [12–14]. Other
protocols have used the forced expression of transcription
factors or microRNA expression to generate robust OPCs
that can mature faster. For example, Ehrlich et al. [20]
reported that the induction of the transcription factors
SRY-box 10 (SOX10), oligodendrocyte transcription factor
2 (OLIG2), and NKX6.2 in iPSC-derived neural progeni-
tors accelerates oligodendroglial differentiation signifi-
cantly resulting in up to 70% of oligodendrocyte marker
O4-positive (O4+) oligodendrocytes within 28 days. These
oligodendrocytes can myelinate the CNS during develop-
ment and after demyelination. Garcia-Leon et al. [21]
demonstrated that overexpression of SOX10 was sufficient
to generate O4+ and myelin basic protein (MBP)-positive
(MBP+) OLs from human iPSCs in only 3 weeks, includ-
ing from patients with amyotrophic lateral sclerosis and
multiple sclerosis. The SOX10-induced O4+ population
resembled primary human oligodendrocytes at the tran-
scriptome level and could myelinate neurons in vivo.
Nazari et. al. [22] reported that hiPSCs treated with micro-
RNA (mRNA)-338 were differentiated into OPCs after
treating for 16 days with basic fibroblast growth factor
(bFGF), epidermal growth factor (EGF), and platelet-de-
rived growth factor (PDGF)-AA. These protocols have an
important use in many of the applications such as in vitro
screening for drugs that promote OL maturation and
myelination and disease modeling. Identifying the critical
pathways that promote OPC generation and oligodendro-
cyte differentiation, and identifying small molecules that
modulate that pathway, may provide an alternative proto-
col that carries a translation potential as well.
Interestingly, a fate-mapping study of adult NSCs in a
cuprizone-induced demyelination mouse model revealed
that there is a downregulation of the SHH pathway
downstream of GLI1 in the NSCs residing in the CNS
prior to their differentiation and mobilization to the
demyelination site. Notably, these GLI-expressing and
SHH-sensitive NSCs were the only subpopulation of
NSCs within the subventricular zone (SVZ) that mi-
grated and remyelinated the lesion [23]. They also
observed that myelination started earlier during develop-
ment in mice that had partial genetic ablation of GLI1 in
NSCs [23]. This suggested that the temporal partial
inhibition/activation of the SHH regulatory pathway
(rather than the continuous activation) is required for
oligodendrocyte development and maturation from
NSCs in the adult mouse brain. In this study, we demon-
strate that a transient and selective partial inhibition of
GLI1 by the small molecule GLI1 inhibitor GANT61 in
early stages of NSC formation followed by SHH pathway
activation by the SMO agonist purmorphamine gener-
ated OLIG2-expressing OPCs that are more migratory
and differentiated earlier than control OPCs. Partial in-
hibition of GLI1 by GANT61 during NSC induction
from human iPSCs (referred to as GANT61 NSC-de-
rived OPCs) results in greater upregulation of OPC and
myelin-associated genes compared to controls during
OPC differentiation. Single-cell RNA sequencing showed
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that the cytoskeletal reorganization pathways involved in
morphological changes during oligodendrocyte differen-
tiation and maturation pathways were activated earlier
in GANT61 NSC-derived OPCs compared to control.
GANT61-derived OLs were functional and could myeli-
nate rat dorsal root ganglion (DRG) neurons in vitro and
shiverer mouse corpus callosum.
Materials and methods
OLIG2-hiPSC and OLIG2-hESC cultures
We utilized two OLIG2-GFP knockin human pluripotent
stem cell reporter lines (OLIG2-hESC and OLIG2-
hiPSC) to follow the OLIG2+ precursors by live fluores-
cent imaging. The OLIG2-hESCs and OLIG2-hiPSCs
have a GFP reporter inserted into one allele of the
OLIG2 gene locus as previously described by our lab
[24], which allow us to isolate OLIG2+ cells by the
expression of GFP.
All experimental procedures conducted on hiPSCs and
hESCs were approved by the University of California at
Davis Stem Cell Research Oversight Committee. hiPSCs
and hESCs were maintained in feeder-free and serum-
free culture conditions on human pluripotent stem cell-
qualified Matrigel matrix-coated (Corning, USA, growth
factor-reduced type) 6-well plates using the mTeSR™1
medium (STEMCELL Technologies, USA) in 37 °C
incubator with 5% CO2.
Neural induction
A schematic diagram of the timeline of OLIG2-NSC and
OLIG2-OPC generation and differentiation is shown in
Fig. 1a. First, in the neural induction phase, we generated
NESTIN+/SOX2+ NSCs (generated from neural rosette-
like structures in adherent cultures) by exposing adherent
cultures of hiPSCs from day 0 to 5 to the neural induction
media (NIM) containing all-trans retinoic acid (RA,
0.1 μM), and dual SMAD signaling inhibitors SB431542
(10 μM) and LDN193189 (250 nM) [12, 25]. Beginning on
day 6, cells were cultured in N2 media containing all-trans
RA (0.1 μM), and the SMO agonist purmorphamine
(1.0 μM) added fresh daily to the medium to pattern these
NSCs to mimic the ventral spinal cord OLIG2+/pre-motor
neuron domain. The cells were cultured in N2B27 media
containing RA (0.1 μM) and purmorphamine (1.0 μM)
from day 9. The induction of OLIG2 expression was
tracked visually by the appearance of GFP expression
under a fluorescence microscope (Fig. 1d, top panel). On
day 14, the OLIG2-GFP-positive cells were detected and
were further enriched and matured by expansion as oligo-
spheres in ultralow attachment plates in PDGF-AA
medium. Non-GFP-expressing cells were unable to form
spheres and were excluded by centrifugation. OPC matur-
ation was induced by replacing the PDGF-AA medium by
the glial differentiation medium (GDM) under adherent
culture in poly-D-lysine/growth factor-reduced Matrigel-
coated dishes or coverslips.
Pharmacological inhibition of GLI1
We have used GANT61 for partial inhibition of Gli1
transcriptional activity based on our own pilot study and
on published data. GLI1 is a specific target for the small
molecule inhibitor, GANT61, which binds directly to the
GLI1 protein and not to the DNA or to other zinc finger
transcription factors. GANT61 is a hexahydropyrimidine
derivative, namely 2-[[3-[[2-(dimethylamino)phenyl]-
methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-
dimethylaniline (molecular formula is C27H35N5 and
molecular weight is 429.60). It is soluble in DMSO and
ethanol. GANT61 can efficiently block GLI1 transcrip-
tion. In our case, we observed a modest (~ 30%) cytotox-
icity between 5 and 10 μM, and the EC50 was 1.75
(Additional file 1: Figure S1.A). In our pilot study, we
found that 5 μM and 10 μM GANT61 reduced the
mRNA expression of GLI1 by 30% and 60%, respectively,
in NSCs (Additional file 1: Figure S1B). Also, 5-μM
GANT61 could prevent the induction of SHH pathway-
dependent olig2 expression in NSCs (as shown earlier in
Fig. 1d, third panel). Thus, the concentration of 5 μM
GANT61 was selected based on the viability curve and
the reduction of GLI1 mRNA expression (Add-
itional file 1: Figure S1.A and B). In one set, GANT61
(5 μM), a selective SHH-GLI1 inhibitor was added during
the neural induction phase in the NIM medium from day
0 to 5 along with the dual SMAD inhibitors and RA. On
day 6, GANT61 was withdrawn and the SHH pathway was
restimulated by adding the SMO agonist purmorphamine
(1 μM along with RA (0.1 μM)) for the generation of
OLIG2+ glial progenitors (from day 6 to 14). In another
set, GANT61 (5 μM) was applied during the glial induction
phase (day 6–14). Specifically, GANT61 was added along
with purmorphamine on days 6–14 of the differentiation
timeline. OPCs from both control and GANT6 groups
were expanded as oligospheres in PDGF-AA medium.
Immunofluorescence staining
The cells were cultured on poly-D-lysine/Matrigel-coated
(growth factor-reduced) coverslips. The immunofluores-
cence staining of hPSC-derived NSCs, OPCs, and oligo-
dendrocytes was performed using the following primary
antibodies: anti-NESTIN (Santa Cruz Biotechnology,
USA), anti-sex determining region Y-box 2 (SOX2)
(Millipore, USA), anti-NG2 (Santa Cruz Biotechnology,
USA), anti-GFP (Millipore, USA), anti-PDGFR-α (Santa
Cruz Biotechnology, USA), anti-galactosylceramidase
(GALC) (Santa Cruz Biotechnology, USA), anti-O4
(R&D Systems, USA), anti-MBP (R&D Systems, USA),
anti-myelin oligodendrocyte glycoprotein (MOG) (Santa
Cruz Biotechnology, USA), anti-proteolipid peptide
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(PLP1) (Santa Cruz Biotechnology, USA), and anti-Glial
fibrillary acidic protein (GFAP) (Santa Cruz Biotechnol-
ogy, USA) as per manufacturer’s recommendations.
Alexa Fluor 488, 545, 595, or 647 conjugated secondary
antibodies (Thermo Fisher Scientific, USA, 1:1000) were
used. In brief, coverslips were washed with Dulbecco’s
phosphate-buffered saline (DPBS) and fixed with 4% para-
formaldehyde (PFA) for 15min at room temperature. The
cells were permeated by 0.25% Triton X-100 for 10min at
room temperature and blocked with 1% bovine serum
albumin (BSA) in DPBS. The primary antibodies were
stained overnight at 4 °C and washed three times prior to
secondary antibody staining for 30min at room
temperature. The coverslips were mounted with Fluoro-
mount-G containing the nuclear stain DAPI (Southern
Biotech, USA). The images were taken by a Nikon C1
confocal microscope.
Flow cytometry
Cells were stained with different oligodendrocyte lineage
markers according to standard published protocols for
flow cytometry. In brief, GFP+/OLIG2+ OPCs were enzy-
matically digested by Accutase enzyme mix (STEMCELL
Technologies, USA) to obtain single cell suspension.
Cells were then pelleted by centrifugation at 500g for 5
min at 4 °C and then resuspended at a concentration of
1–5 × 106 cells/mL in ice-cold 10% BSA in DPBS
solution. Cells were then strained through a 40-μm cell
strainer prior to flow cytometry. Analysis of GFP
expression and various oligodendrocytes markers was
performed on the Attune NxT Acoustic Focusing Cyt-
ometer (Thermo Fisher Scientific, USA), and data were
analyzed with the AttuneTM NxT software. Background
fluorescence was excluded using unstained vehicle con-
trol OPCs. For each sample, more than 10,000 events
were recorded and were used to evaluate the percentage
of GFP-expressing cells and different OPC and oligo-
dendrocyte population.
Viability assay
Double live/dead cell staining buffer containing calcein-
AM and propidium iodide (Dojindo Molecular Tech-
nologies, USA) was added to the cell. A fluorescence
plate reader detector (Perkin Elmer, USA) for 96-well
plates was used to measure the live/dead cells and calcu-
late the relative cell viability. In a separate set of experi-
ments, propidium iodide (PI) dye inclusion method was
used to identify dead cells measured by the Attune NxT
Acoustic Focusing Cytometer (Thermo Fisher Scientific,
USA). Live/dead cell double staining can be utilized for
simultaneous fluorescence staining of viable and dead
cells. Calcein-AM is a highly lipophilic and cell mem-
brane-permeable dye. Though calcein-AM itself is not a
fluorescent molecule, the calcein generated from calcein-
AM by esterase in a viable cell emits a strong green fluor-
escence (λex 490 nm, λem 515 nm). Therefore, calcein-
AM only stains viable cells. Alternatively, the nuclei stain-
ing dye propidium iodine cannot pass through a viable cell
membrane. It reaches the nucleus by passing through dis-
ordered areas of the dead cell membrane and intercalates
with the DNA double helix of the cell to emit red fluores-
cence (λex 535 nm, λem 617 nm). Since both calcein and
PI-DNA can be excited with 490-nm light, simultaneous
monitoring of viable and dead cells is possible with a
fluorescence microscope.
Cell proliferation assay
Cell proliferation was assayed by the SYTOX® Blue dead
cell stain kit (Invitrogen, USA). SYTOX® Blue is a high-
affinity nucleic acid stain that penetrates cells with com-
promised plasma membranes but will not cross intact
cell membranes. After incubation with 1 μM SYTOX®
Blue stain for 5 min at room temperature, protected
from light, the nucleic acids of dead cells fluoresced
bright blue when excited with 405-nm violet laser light.
The cells were then analyzed without fixing with either a
440/40-nm or a 530/30-nm band-pass filter with the
Attune NxT Acoustic Focusing Cytometer (Thermo
Fisher Scientific, USA). In another set, the rate of prolif-
eration was assessed after the incubation period follow-
ing staining with CellTrace Violet (Thermo Scientific,
USA) according to the manufacturer’s instructions.
Cell migration
Oligospheres (expressing PDGFR-α at day 34 of differen-
tiation) of similar sizes from both control and GANT61
groups were plated on poly-D-lysine/Matrigel-coated
(growth factor reduced) glass coverslips in GDM
medium. The spheres were allowed to attach to the
coverslips for 2 h in few drops (~ 100 μL) of the medium
in a petri dish. After 2 h, the coverslips were placed into
individual wells of a 24-well plate with fresh 1 mL GDM.
After 2, 24, and 48 h of plating, 15 oligospheres from
each group were imaged, and the distances traveled by
various cells were imaged under an inverted microscope
and measured and analyzed by ImageJ.
The real-time semiquantitative PCR (RT-PCR) analysis
Total RNA was extracted from the cells in cultures using
the RNeasy Mini Kit (Qiagen, USA). cDNA was synthe-
sized using the qScriptTM XLT cDNA SuperMix
(Quanta Bio, USA), and qPCR was performed using the
PerfeCTa® SYBR® Green SuperMix and Low ROX
(Quantabio, USA) running on the MX30005p light
cycler system (Stratagene, USA). Expressions of all the
genes were normalized to the expression of the house-
keeping gene GAPDH. The list of the primers (Invitro-
gen, USA) is included in Additional file 6: Table S1.
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Dorsal root ganglion neuron co-culture with GANT61
derived OPCs
Rat DRGs (Lonza Inc., USA) were plated on collagen type
I-coated coverslips and allowed to mature for 2 weeks in
primary neuronal growth medium (Lonza Inc., USA). Rare
contaminations of rat OPCs were eliminated by continu-
ous exposure to medium containing 5-fluorodeoxyuridine
0.1 μM and uridine 0.1 μM. GANT61-NSCs were differen-
tiated to PDGFR-α-expressing OPCs. OPCs were then
plated on top of the DRG neurons and cultured in GDM
medium. After 3 weeks of co-culture, the cells were fixed
and processed for electron microscopy (EM) imaging. All
experiments were performed in accordance with relevant
guidelines and regulations set by the University of
California, Davis.
Transplantation of GANT61-derived OLIG2/GFP-OPCs in
shiverer mouse brain
Shiverer mice (C3Fe.SWV-Mbpshi/J, The Jackson La-
boratory, USA) lack MBP and compact myelin in the
CNS. Therefore, these mice serve as a good model to
test the functional capacity of transplanted OPCs toward
forming MBP-positive compact myelin sheath around
axons. Shiverer mice 8–10 weeks old (N = 3; 2 males, 1
female) were injected with 50,000 iPSC-derived
GANT61-OLIG2+/GFP+/PDGFR-α+ OPCs. Mice were
deeply anesthetized by a cocktail of ketamine (70 mg/kg)
and xylazine (10 mg/kg). Then, 1 μL of cell suspension
was injected aseptically (at the rate of 0.3 μL/min) into the
corpus callosum using a Hamilton syringe at the following
stereotaxic coordinates: anteroposterior 0.2, mediolateral
1.1 with Bregma as a reference, and dorsoventral 2 mm
from the skull surface. Mice were administered cyclo-
sporin 10mg/kg daily intraperitoneally for immune sup-
pression, beginning 2 days before cell transplantation until
sacrifice. Postoperative care was given according to the In-
stitutional Animal Care and Use Committee (IACUC)
protocols approved by the University of California, Davis.
Mice were sacrificed after 4 or 6 weeks, and the corpus
callosum sections (2–3mm) containing the injection site
was microdissected and processed for imaging under an
electron microscope or for confocal imaging.
The single-cell RNA sequencing (RNA-Seq)
Oligospheres at day 39 (OLIG2/GFP+ spheres were ac-
tually collected at day 24 of differentiation and expanded
in PDGF-AA media for 2 weeks in suspension) were
dissociated into single cells using the cell dissociation
enzyme Accutase (STEMCELL Technologies, USA).
Briefly, Accutase was added to the culture wells contain-
ing the spheres and incubated at room temperature for
5–10 min. Next, the culture dishes were placed in a cell
culture incubator at 37 °C for 5 min for the inactivation
of Accutase enzyme. Spheres were then gently triturated
with a glass pipette to dissociate the spheres into single
cells. Then, they were passed through a 40-μm cell
strainer to obtain single cell suspension. The single-cell
RNA library was prepared by sorting the single cells
onto a 96-well plate prefilled with BD™ Precise Library
Prep Kit Buffer. Fluorescence-activated cell sorting
(FACS) was done by the UC Davis Flow Cytometry Core
Facility. Ninety-six individual OPCs from the control
group and 96 GANT61 OLIG2/GFP-OPCs were se-
quenced. The sequencing was carried out on the Next-
Seq Illumina platform using a 75-bp paired-end, and a
speed of 350,000 reads per cells, by UC Davis Genome
Center core services. The sequence reads were analyzed
on the Seven Bridges Genomics Platform using a WTA
Precise computation pipeline and were aligned to the
GRCh37/hg19 human reference genome. The sequence
reads were normalized with the Bioconductor R pack-
ages zero-inflated negative binomial model (ZinB) [26]
prior to determining the differential gene expressions
(DEGs). One thousand highly variable genes were re-
cruited for DEG analysis by the Empirical Analysis of
Digital Gene Expression Data in R (EdgeR) software [27].
Subsequent Gene Ontology (GO) of the DEGs was per-
formed using the Database for Annotation, Visualization
and Integrated Discovery bioinformatics resource [28].
Cell culture media
The following are the cell culture media:
– mTeSR1: mTeSR1 basal medium was supplemented
with 50× mTeSR1 supplement and 100× penicillin-
streptomycin to get the final concentration of 1× each.
– Basal medium: DMEM/F12 supplemented with non-
essential amino acids (NEAA) 1×, GlutaMAX 2mM,
2-mercaptoethanol, and penicillin-streptomycin to
get the final concentration of 1x each.
– Neural Induction Medium (days 0–5): basal medium
supplemented SB431542 10 μM () LDN193189 (250
nM) and RA (0.1 μM).
– N2 medium: basal medium supplemented with N2
supplement (Gibco, USA, 100× stock) to get a final
concentration of 1× N2, laminin 4 μg/mL (Roche,
Switzerland), bFGF 10 ng/mL (Peprotech, USA), and
Noggin 20 ng/mL (Peprotech, USA). RA 0.1 μM (Sigma-
Aldrich, USA) and purmorphamine 1 μM (Cayman,
USA) were added fresh during medium change.
– N2B27 medium (days 10–14): basal medium
containing 1× of N2 (Gibco, USA, 100× stock) and
1× of B27 (Gibco, USA, 50× stock) supplements. RA
was removed in this step. One micromolar
purmorphamine was added fresh during media
change.
– PDGF-AA medium: basal medium containing 1× N2
(Gibco, USA, 100× stock), 1× B27 (Gibco, USA, 50×
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stock) supplements, biotin 100 ng/mL (Sigma-
Aldrich, USA), PDGF-AA 10 ng/mL (Peprotech,
USA), IGF-1 10 ng/mL (Peprotech, USA), T3 60 ng/
mL (Sigma-Aldrich, USA), NT3 10 ng/mL
(Peprotech, USA), HGF 5 ng/mL (Peprotech, USA),
and cAMP 1 μM (Sigma-Aldrich, USA).
– Glial differentiation medium (GDM): basal medium
containing 1× N2, 1× B27 supplements, biotin 100
ng/mL (Sigma-Aldrich, USA), T3 60 ng/mL (Sigma-
Aldrich, USA), ascorbic acid 20 μg/mL (Sigma-
Aldrich, USA), NT3 10 ng/mL (Peprotech, USA),
HEPES 10mM (Sigma-Aldrich, USA), cAMP 1 μM
(Sigma-Aldrich, USA), Y-27632 10 μM (Cayman,
USA), and heregulin 10 ng/mL (Peprotech, USA).
Statistical analysis
Statistical analyses are performed using the independent
t test for two-sample comparison or one-way analysis of
variance (ANOVA) with post hoc Bonferroni test for
three-sample comparison (Prism6, version 6.01). The
experiments were done in triplicate unless mentioned
otherwise. Values are expressed in each graph as the
mean ± SEM. The differences between mean values for
different treatments are considered to be significant at
P < 0.05 (presented as “*”), at P < 0.01 (presented as “**”),
and at P < 0.001 (presented as “***”).
Results
SHH signaling pathway genes are differentially expressed
in the hiPSCs, hiPSC-derived NSCs, and hiPSC-derived OPCs
We evaluated the mRNA expression of key SHH pathway
genes in hESCs, NSCs, and OPCs generated according to
the timeline (Fig. 1a). Human iPSC cell line and the hESC
line were grown on Matrigel-coated plates in E8 media
and then differentiated into NSCs and olig2-expressing
oligospheres and finally OPCs (Fig. 1b). Specifically, we
measured the mRNA expression levels of the SHH signal-
ing receptors Smoothened (SMO) and Patched1 (PTCH1),
and their downstream effector’s transcription factors
(TFs) GLI1, GLI 2, and GLI3 (Fig. 1c).
We detected low levels of mRNA GLI1, GLI 2, and
GLI3 in undifferentiated hiPSCs (n = 3) as expected
since the GLI TFs are thought to play a minimal role in
the maintenance and self-renewal of hiPSCs and hESCs
(Fig. 1c). Next, we looked at the expression levels of the
mRNA for GLI1, GLI 2, GLI3, Smoothened (SMO) and
Patched1 (Ptch1) in hiPSC-derived NSCs that were gen-
erated after hiPSCs were exposed to RA and dual SMAD
inhibitors in NIM media at day 5 (Fig. 1c). We found
that in the SOX2+ and NESTIN+ NSCs, GLI1 and GLI3
mRNAs were upregulated by 5.5- and 9-folds, respect-
ively, compared to undifferentiated hiPSCs (P < 0.001 for
both GLI1 and GLI3) (Fig. 1c). The expression of GLI2
was not significantly different between undifferentiated
hiPSCs and derived NSCs (Fig. 1c). A similar expression
pattern was also observed in the OLIG2-hESC-derived
NSCs (shown in Additional file 1: Figure S1.C). Thus, we
confirmed that SHH signaling pathway genes were
highly transcribed during the differentiation of hPSC to-
ward the NSCS. Other studies have also shown that the
SHH is a critical regulator of NSC formation and later
their specification toward OPC fate during mammalian
brain development [3, 6, 19, 29–31].
Next, we patterned the hiPSC-derived NSCs with RA
and the Smoothened agonist purmorphamine to mimic
the ventral spinal cord NSCs which generate OLIG2+
progenitors (green cells) expanded as oligospheres
(Fig. 1b). OLIG2+ progenitors differentiate into motor
neurons and later OPCs in vitro and in vivo. At day 14
of the differentiation timeline, GLI1, GLI3, and Ptch1
mRNA levels in early OPCs were further upregulated
compared to NSCs measured at day 5 (P < 0.05, P < 0.01,
and P < 0.001, respectively) (Fig. 1c). These results indi-
cated that the SHH pathway genes were differentially
transcribed during the neural and glial induction phases.
Partial inhibition of GLI1 by GANT61 in NSCs during
the glial induction phase (even in the presence of the
Smoothened agonist) inhibited the generation of
OLIG2+ glial progenitors in vitro
In an effort to investigate the effect of partial inhib-
ition of the SHH pathway on OL development and mat-
uration, we first sought to explore the effects of partial
inhibition of GLI1 during the glial induction phase. Typ-
ically, the stimulation of the SHH pathway in the NSCs
(in our case with the Smoothened agonist purmorpha-
mine during days 6–14) is critical for glial induction in
vitro (seen by the generation of OLIG2/GFP-positive
glial progenitors) (Fig. 1d, top panel), since OLIG2/GFP
progenitors were not generated in vitro in the absence of
purmorphamine (Fig. 1d, second row). Therefore, we
treated the NSCs with GANT61 during the glial pro-
genitor induction phase (days 6–14 of the differentiation
timeline). We found that 5 μM GANT61 prevented the
generation of OLIG2+/GFP+ OPCs (Fig. 1d, third row),
to a level that is seen in the complete absence of pur-
morphamine. Thus, we concluded that partial inhibition
of GLI1 signaling pathway during glial induction inhib-
ited the generation of glial progenitors.
Partial inhibition of GLI1 by GANT61 during neural
induction phase results in greater upregulation of OPC
and oligodendrocyte genes compared to controls OPC
Next, we partially inhibited GLI1 early during the neural
induction phase (days 1–5). hiPSCs were treated with
5 μM GANT61 or dimethyl sulfoxide (DMSO) vehicle
control together with all-trans RA and dual SMAD
inhibitors for neural induction. We observed that GLI1
mRNA levels were significantly reduced in the NSCs
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that were generated at day 5 (P < 0.001 compared to
control NSCs) but GLI2 levels were not different com-
pared to control NSCs (Fig. 2a, b, respectively).
We then sought to characterize and differentiate these
NSCs that were generated in the presence of transient
partial GLI1 inhibition (refer to as GANT61-NSCs). We
found that both GANT61-NSCs and control-NSCs
(DMSO vehicle control) differentiated into NESTIN+/
SOX2+ NSCs with similar efficiency (Fig. 2c–e). The
populations of Nestin+ and Sox2+ NSCs were similar be-
tween control-NSCs and GANT61-NSCs (Fig. 2d, e).
GANT61-NSCs also showed no difference in cell viabil-
ity and rate of proliferation compared with control NSCs
(Fig. 2f, Additional file 3: Figure S3A). Similar results
were seen with hESC-derived NSCs (Additional file 1:
Figure S1.D and E).
We observed that the GANT61-NSCs were able to
give rise to OLIG2+/GFP+ OPCs, which could be main-
tained and expanded as GFP+ oligospheres (green
spheres) (Fig. 1c first and second row, also see SHH
genes expression in Additional file 2: Figure S2.A-E).
Similar results were seen in the Olig2-knockin H9 hESC
line (Additional file 4: Figure S4.A). We used flow cy-
tometry to count the percentage of OLIG2-GFP+ and
NG2 co-expressing glial cells in control-NSCs and
GANT61-NSCs (n = 3). The NG2+ OPC population is
Fig. 1 a The experimental timeline of oligodendrocyte differentiation from hiPSC colonies. b Phase bright images of iPSC colonies, neurorossette
formation on day 5, oligospheres in suspension cultures, and O4+ Pre-OLs. c Expression pattern of SHH pathway genes in undifferentiated hiPSC,
hiPSC-derived NSCs, and OLIG2-OPCs (three independent RT-PCR assays, n = 3, t test). d The generation OLIG2+/GFP+ glial progenitors (on day 14)
following purmorphamine treatment in NSCs from day 6 to 14 (top row) and the absence of OLIG2/GFP induction without purmorphamine (second
row); GANT61 treatment in NSC concomitant with purmorphamine (from day 6 to 14) did not give rise to OLIG2/GFP glial progenitors (third row), and
GANT61 treatment from day 0 to 5 followed by purmorphamine (days 6–14) gave rise to OLIG2+/GFP+ glial progenitors (fourth row). The images in d
is a representation of three independent experiments. Scale bar, 100 μm. Error bars indicate SEM. ***P < 0.001; **P < 0.01; *P < 0.05 vs. day 0
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considered as the oligodendrocyte progenitors in the
mammalian CNS [5]. We found that the population of
NG2+/GFP (OLIG2)+ was not significantly different
between both groups (see Additional file 2: Figure S2.F
and G). However, we noticed a difference in the intensity
of GFP expression (Fig. 2g). Since the GFP gene was
knocked-in under the OLIG2 locus in hiPSCs (and
hESCs), the green fluorescence is a read-out of OLIG2
promoter activity and OLIG2 gene expression. In the
NSC that were patterned toward OPC, two populations
of GFP+ OPCs were identified in both GANT61-OPC
and control-OPC (day 14), one with a lower level of GFP
expression and the other with relatively brighter GFP
expression. Whereas, control-NSCs (day 9) had a nom-
inal fraction of cells (~ 3% of all events, n = 3) that
expressed GFP+ (Fig. 2g, left panel). In control OLIG2-
OPCs, 13.6 + 1.14% of all GFP+ cells were GFP bright
while in GANT61-OPCs, 30.0 + 1.4% were GFP-bright
cells (P < 0.001, n = 3, conducted three independent ex-
periments, Fig. 2g) with no significant differences in the
cell viability, but had slightly lower proliferation rate
(Additional file 3: Figure S3.B). To test if the greater
Fig. 2 The relative mRNA expression at day 5 of a GLI1 and b GLI2 vs. undifferentiated hiPSCs in the absence and presence of GANT61 (n = 3, t
test). c Representative immunocytochemistry images of NESTIN+/SOX2+ in control and GANT61-NSCs (day 5). Quantification of d NESTIN and e
SOX2+ cells in control-NSCs and GANT61-NSCs (at day 5 of differentiation, n = 5 independent experiments). f Analysis of cell survival following
GANT61 treatment from day 0 to 5 (assayed at day 5, n = 5). g A representative flow cytometry data of GFP/OLIG2 expression in NSC-derived
OPCs (day 14, n = 3 independent experiments). h–j The gene expression of the transcription factors, NKX2.2 OLIG2 and SOX10, in GANT61-OPCs
compared to control-OPCs (assayed at day 14, n = 3, t test.). Data are shown as fold change relative to the expression in NSC (n = 3, t test). Error
bars indicate SEM. ***P < 0.001; **P < 0.01; *P < 0.05
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GFP-bright population reflects higher OLIG2 mRNA ex-
pression, we assayed mRNAs of FACS-sorted GFP+
OPCs (day 14) by RT-PCR and found that GANT61
OLIG2-OPCs expressed higher levels of mRNAs for the
key OPC transcription factor genes OLIG2, SOX10, and
NKX2.2 compared to control OLIG2-OPCs (Fig. 2h–j).
This indicated that early transient inhibition of GLI1 in
NSCs leads to a greater upregulation of the critical
oligodendrocyte developmental genes later in the pres-
ence of Smoothened agonist purmorphamine.
The higher levels of OPC-related gene expression and
an increase in the GFP-bright subpopulation (higher
reporter mRNA and protein expression indicating higher
activation of OLIG2 gene) prompted us to hypothesize
that the pattern and timeline of differentiation of OPCs
from hiPSCs (or hESCs) is a program that may be already
in place during the early phases of NSC generation, and
maybe modulated by GLI1 early during NSC formation.
Next, to study the effect of GANT61 on OL differenti-
ation, we differentiated the control and GANT61
OLIG2-OPCs and followed the percentage of cells at
different stages of maturation by the expression of the
stage-specific immune markers by flow cytometry
(Fig. 3a). Similar numbers of OLIG2-OPCs from control
and GANT61 groups were initially plated on the poly-D-
lysine/Matrigel-coated (growth factor-reduced) dish at
25% confluence and differentiated for up to 59 days. The
percentage of PDGFR-α+ OPCs was similar in both
groups at days 34–35 of the differentiation timeline. The
late OPC marker O4 (referred to as Pre-OL) was
detected as early as day 45 (31.5 + 1.5% in GANT61
compared to 6.5 + 1.1% in the control group (P < 0.001),
n = 3). At day 59 of differentiation timeline, the fraction
of cells expressing immature oligodendrocytes markers
GALC and mature oligodendrocyte marker MBP in the
GANT61 group was 74.2 + 0.5% and 31.3 + 0.5%, re-
spectively, compared to control cells which were 31.2 +
0.7% and 25.4 + 0.6%, respectively (P < 0.001 for both
markers, n = 3). The immunofluorescence staining of
oligodendroglial markers was done at the same time
frame (Fig. 3). We also repeated the study in the olig2-
knocked-in H9 hESC line and found that the percentages
of the PDGFR-α-expressing cells at day 34 in both
GANT61 and control were 74.5 + 2.4% and 73.3 + 2.6%,
respectively, while the percentage of GALC-expressing
mature OL was significantly higher in the GANT61 group
at day 59 (48.1 + 2.0 vs. 13.4 + 4.1 in control, n = 3, see
Additional file 4: Figure S4.B and C).
At day 59 of differentiation, GANT61-derived oligo-
dendrocytes showed upregulated levels of SOX10 and
OLIG2 by 3.4-folds (P value = 0.005) and 2.6-folds (P
value = 0.003), respectively, compared to the control-de-
rived oligodendrocytes (RT-PCR assay, n = 3) (Fig. 3c, d).
This was associated with a concurrent increase in myelin
gene, i.e., myelin-associated glycoprotein (MAG) by 3.5-
fold (P value = 0.005, n = 3), MOG by 2.7-folds (P value =
0.014, n = 3), and MBP by 3.2-fold (P value = 0.039, n =
3), (Fig. 3e–h). Together, these results indicate that
around day 59, control OLIG2-OPCs show limited mat-
uration whereas GANT61-derived OLIG2-OPCs were
capable of maturing toward advanced stages by inducing
the expression of critical transcription factors and mye-
lin genes.
Transient inhibition of GLI1 during NSC formation later
promotes the generation of OPCs that are more
migratory than control OPCs
The migratory capacities of the PDGFR-α+ GANT61
OLIG2-OPCs and control OLIG2-OPCs were tested on
poly-D-lysine/Matrigel-coated surfaces by measuring the
distance traveled by the OPCs radiating out of oligo-
spheres after attachment for 2, 24, and 48 h (Fig. 3i). The
initial diameters of the plated oligospheres ranged from
200 to 300 μm and were similar between the two groups
(P value = 0.15). The results show that after 48 h, the aver-
age distance of cell migration from GANT61 oligospheres
(96.2 ± 6.5 μm) was significantly greater than vehicle con-
trol-oligospheres (64.3 ± 6.1 μm, P < 0.001)(Fig. 3j). Similar
results were seen with H9 OLIG2-GFP knockin hESC-de-
rived OPCs (GANT61 treatment from day 0 to 5, Add-
itional file 4: Figure S4.D and E). In the OLIG2-GFP hESC
line, the average distance of migration was 107 + 4.0 μM,
while in the control group, the distance was 61.0 + 5.5 μM
(P < 0.001). This result indicates that early transient inhib-
ition of GLI1 during NSC induction followed by reactiva-
tion of the SHH pathway by purmorphamine gave rise to
the OPCs with relatively greater migratory capacity after
glial differentiation.
GANT61-derived oligodendrocytes showed upregulation of
cytoskeletal reorganization pathway revealed by single-cell
whole transcriptomic analysis
To understand the mechanistic insight into the pathways
that may have contributed to the early maturation of
GANT61-derived oligodendrocytes, we performed single-
cell whole transcriptomic expression profiling on
GANT61-OPCs (identified by PDGFR-α+, days 39–40).
Two hundred thirty-four genes were identified as showing
significantly different expression levels in response to
GANT61 (FDR < 0.01). Of these, 24 genes were found to
be upregulated (logFC > 1.2) and 49 genes as downregu-
lated (logFC < 1.2) (Fig. 4a, Additional file 7). The GO
terms that were found to be significantly enriched in the
GANT61-OPCs were “cytoskeleton organization (GO:
0007010),” “cellular response to transforming growth
factor beta stimulus (GO:0071560),” “stress fiber (GO:
0001725),” “filopodium (GO:0030175),” “ruffle membrane
(GO:0032587),” “actin binding (GO:0003779),” and
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“laminin binding (GO:0043236)” (Fig. 4b, Additional file 8).
On the other hand, the GO significantly downregulated in
GANT61 were “basement membrane (GO:0005604)” and
“intermediate filament cytoskeleton (GO:0045111)” (Fig. 4c,
Additional file 9). Among the upregulated genes, particu-
larly actin-related protein 2/3 complex subunit (also known
as ARPC2 and ARP2/3), metallopeptidase inhibitor 1
(TPM1), integrin subunit beta 1 (ITGB1), and dystonin
Fig. 3 a Percentages of PDGFR-α+ OPCs (day 34), O4+ pre-oligodendrocytes (days 45–47), GALC+ immature oligodendrocytes (day 59), and
MBP+ mature oligodendrocytes (day 59) (n = 3, three independent experiments). b The representative immunocytochemistry images of
oligodendroglial protein expressions of PDGFR-α, O4, GALC, and MBP (three independent experiments were done). c–h The mRNA levels of MBP,
PLP1, SOX10, OLIG2, MAG, and MOG at day 59 of oligodendrocyte differentiation timeline (n = 3). i Representative images of cells migrating out of
spheroid at 2, 24, and 48 h after attachment to the culture plate (three independent experiments were done). j Quantification of cell migration
distance (n = 3, ANOVA followed by t test). (Scale bar = 100 μm; n = 15, t test). Error bars indicate SEM. *P < 0.05; ***P < 0.001
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Fig. 4 (See legend on next page.)
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(DST) were of particular interest (see the expression of indi-
vidual genes from single-cell transcriptomic analysis,
Fig. 4d). The actin filament assembly drives the oligo-
dendroglial process extension and ensheathment of the
axon, they are important for the early stages of the oligo-
dendroglial process branching [32–34]. The upregulation
and interaction of laminin on β1 integrin promote oligo-
dendroglial survival [35, 36] and formation of myelin sheath
[37]. On the other hand, the reduction in DST expression
found in GANT61-OPCs may associate with the halt of
OPC, but not related to oligodendroglial maturation as
previously described by Hossain et al. [38]. Thus, the effects
of early transient inhibition of GLI1 in NSCs on subsequent
differentiation into oligodendrocytes seems to involve the
greater activation of the pathways that promote cytoskel-
eton rearrangement geared toward initiation of the forma-
tion of mature branched structures and enhance motility.
GANT61-NSC-derived oligodendrocytes are capable of
forming multilayered myelin in vitro and in vivo
Following terminal differentiation, GANT61-oligodendrocytes
differentiated into the cells with extensive sheet-like appear-
ance and expressed myelin basic protein (MBP) (Fig. 4e, f).
The myelination capacity of GANT61-oligodendrocytes
was tested in the rat dorsal root ganglion cells (DRGs) co-
culture model (n = 3), and also after transplantation into
myelin-deficient shiverer mice’s brain (n = 3). In the co-cul-
ture model, the GANT61-derived late OPCs expressing the
O4 marker (Fig. 4g) were plated on top of the rat DRG neu-
rons and cultured in GDM medium for 3 weeks. Transmis-
sion electron microscopy (TEM) of the sections of the co-
cultures (Fig. 4h, i) showed the presence of multilayered
myelin around DRG axons. In the OLIG2-GFP knockin
hESC line, GANT61-treated group generated functional
OLs which were able to myelinate rat DRG neurons in the
co-culture system (see Additional file 5: Figure S5.A).
We also checked the myelination capacity of GANT61-
derived OL to form compact myelin in shiverer mice.
Shiverer mice lack myelin basic protein (MBP) and there-
fore are incapable of making compact multilayered myelin.
GANT61-derived O4+ OPCs transplanted into the corpus
callosum of myelin-deficient mouse shiverer mice were
capable of forming multilayered myelin structures when
studied under an electron microscope 6 weeks after trans-
plantation (Fig. 4j–l). The survival of the transplanted cells
was tested in shiverer mice by the presence of anti-human
nuclear stain and anti-GFP co-labeled cells in the corpus
callosum 1 week after transplantation (Fig. 4m). GANT61-
treated OLIG2-GFP H9 hESC-derived O4+ OPCs after
transplantation into the corpus callosum of MBP-deficient
shiverer mice were able to mature into MBP-producing oli-
godendrocytes after 4 weeks (Additional file 5: Figure S5.
B). OPCs were detected in the corpus callosum by anti-
GFP antibody (green cells), and they co-labeled with MBP
stain (red).
Discussion
In this study, we show that partial inhibition of GLI1 in
hiPSC or hESC during neural induction give rise to
NSCs that can differentiate earlier to mature functional
oligodendrocytes in vitro. We had adopted a previously
described protocol for the generation and isolation of
OPCs from hiPSCs by tracking the expression of OLIG2
gene with the GFP reporter [12]. Adherent hiPSC col-
onies were concurrently exposed to RA and dual SMAD
inhibitors, SB431542 and LDN193189, to generate
PAX6-positive NSCs, which were then patterned toward
OLIG2- and NKX2.2-expressing glial progenitors using
RA and the Smoothened agonist SAG. These OLIG2-
positive glial progenitors can be expanded as oligo-
spheres and differentiated into pre-oligodendrocytes
(identified by the expression of the O4 marker) and
eventually became mature OLs (identified by expression
of MBP) by day 50 and day 75, respectively. This proto-
col allowed us to explore the role of temporal partial in-
hibition of GLI1 signaling during NSC induction or
during glial induction on the timing of OLIG2-positive
OPC generation and maturation since the SHH signaling
pathway has been shown to be involved in oligodendro-
cyte fate determination and maturation [3, 6, 19, 26–28].
First, we confirmed the expression of SHH pathway
genes in human iPSCs (and hESCs) during the formation
(See figure on previous page.)
Fig. 4 a Heat map of top differentially expressed genes (DEGs) expressed in hiPSC-derived oligodendrocytes (representative map from three
independent experiments). Representative Gene Ontology (GO) of b upregulated genes and c downregulated genes in GANT61-OPCs compared to
control OPCs (n = 192). d The expression level of significant DEGs of interest from the single-cell transcriptomic analysis in GANT61 and control OPCs
(n = 192). Representative phase-contrast image of e GANT61-oligodendrocytes and f myelin basic protein (MBP) staining of GANT61-oligodendrocytes.
g The representative phase-contrast image of co-culture GANT61-oligodendrocytes with rat DRG. The cell morphology of two GANT61-
oligodendrocytes (yellow arrow) projected their processes toward the axon of rat DRG (red arrow). The asterisk indicates where the oligodendroglial
membrane initiated to enwrap axonal process, which appeared as the thicker patterns comparing to thinner bare axon or non-myelinated segments.
h Multilayered myelin is seen in co-cultures GANT61-oligodendrocytes with rat DRG under TEM (n = 3). i A higher magnification image of the myelin
sheath showing light and dark bands. j The formation of compact myelin sheath in shiverer mouse brain after transplanted with GANT61-OPCs in the
corpus callosum (n = 3). k, l Higher magnification images of the compact myelin sheaths. m Transplanted cells were detected in the shiverer mouse
brain (in the corpus callosum) by co-labeling with anti-human nuclei antibody (red) and anti GFP stain (green) 2 weeks after transplantation. Error bars
indicate SD, “A” indicates axon. Scale bar g 10 μm; h 500 nm; i, k, l 100 nm; j 1 μm
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of NSCs and their subsequent lineage restriction into
OLIG2-expressing glial progenitors. We confirmed the
earlier findings that there is a significant upregulation of
GLI1 during the generation of NSCs. We found that
GANT61 decreased the mRNA levels of GLI1 signifi-
cantly without changing GLI2 levels (similar to the
results seen by Samanta et al. [23]).
Following initial partial inhibition of GLI1 with
GANT61, the SHH pathway was later restimulated with
the Smoothen agonist purmorphamine in order to in-
duce OLIG2 expression. Both control and GANT61-
NSCs gave rise to OLIG2+/GFP+ glial progenitors. When
the GFP+ OPCs were analyzed by flow cytometry, a
higher percentage of cells emerged in GANT61-OPCs
which showed “high” GFP (OLIG2) expression. This was
confirmed with RT-PCR analysis which showed that
GANT61-derived cells had significantly higher mRNA
levels of the key oligodendroglial fate-determining tran-
scription factors genes OLIG2, as well as of NKX2.2 and
SOX10. After differentiation, the GANT61-derived cells,
however, generated similar numbers of PDGFR-α+ OPCs
when compared to control-OPCs indicating that
GANT61 did not modify the appearance of early OPCs.
After further differentiation, however, GANT61-OPCs
gave rise to a significantly greater number of pre-oligo-
dendrocytes (~ 31.5% O4-expressing cells) compared to
control OPCs which generated ~ 6.5% O4+ cells at day
45. After further differentiation, the fraction of the cells
expressing mature OL markers and GALC+ was around
three- and fivefolds higher in the GANT61-treated
group.
By single-cell whole transcriptome expression profil-
ing, we found that OPCs generated from NSCs in which
GLI1 was transiently and partially inhibited had activa-
tion of genes in the pathways that promote cytoskeleton
rearrangement geared toward the initiation of the
formation of mature phenotypes (branched structures
and enhance motility). Specifically, we performed the
single-cell RNA sequencing assay (RNA-Seq) from
PDGFR-α-expressing OPCs from the control and
GANT61 groups. We also found that the genes associ-
ated with the cytoskeletal reorganization such as ARP2/
3, TIMP1, and ITGB1 were activated in GANT61-OPCs
compared to control-OPCs. This was particularly rele-
vant since oligodendrocyte differentiation is a dynamic
process involving high protrusion remodeling, with cells
undergoing extreme cytoskeleton rearrangements that
follow a cellular shaping program that governs morpho-
logical differentiation [32, 35, 36]. Typically, the oligo-
dendrocytes undergo an initial period of protrusion
remodeling shown by multiple retractions and extension
of the filopodial, followed by the complex branched
structure characteristic of pre-myelinating oligodendro-
cytes [1]. Actin polymerization is shown to be the key
driver for the extension of membrane protrusions ob-
served during terminal maturation of oligodendrocytes
while the ARP2/3 complex, a key nucleator of actin net-
works found in lamellipodia, is required for the exten-
sion of oligodendrocyte protrusions [34, 39–41].
Previous reports have studied the role of the ARP2/3
complex in the migration of progenitor cells found in
the brain. ARP2/3 is required for the directed migration
of NSC-derived oligodendrocyte precursor cells (OPCs)
in an electric field [40]. ARPC2-null OPCs were found
to be slower and have shorter filopodial processes than
ARPC2-expressing OPCs [40].
GANT61-derived oligodendrocytes were shown to be
functional and were able to generate multilayered myelin
sheath around the DRG neurons (in vitro) and in the
corpus callosum of myelin-deficient shiverer mice (n = 3)
after in vivo transplantation.
Recently, Samanta et al. [23] identified a subset of
adult SHH-responsive pool of NSCs in the mouse SVZ
that are recruited specifically to the demyelinated corpus
callosum where they downregulate GLI1 and differenti-
ate into mature, myelinating oligodendrocytes. They
compared the effects of partial and complete downregu-
lation of GLI1 expression by fate mapping NSCs in GLI1
null (GLI1CE/nLacZ; RCE) vs. GLI1 heterozygous
(GLI1CE/+; RCE) mice. The major effects of partial loss
of GLI1 in NSCs appeared to be enhanced differentiation
to oligodendrocytes. Also, partial inhibition of GLI1 in
NSCs (by GANT61-mediated pharmacological inhib-
ition) promoted the maturation of these oligodendro-
cytes and recovery after demyelinating injury. Their
observation that partial downregulation of GLI1 expres-
sion was critical in NSCs to augment maturation and
remyelination contrasted with the studies reporting that
SHH signaling promoted remyelination after CNS injury
and is required for remyelination. Interestingly, they
found that complete inhibition of GLI1 was ineffective in
promoting remyelination, indicating that the role of
GLI1 both in augmenting hedgehog signaling and in
retarding myelination is dose-dependent and highly
specialized. Their study and our current study indicate
that the effects of loss of GLI1 in NSCs appear to be
enhanced differentiation to oligodendrocytes. Also, par-
tial loss of GLI1 has an even greater effect in the context of
active SHH signaling, promoting robust recruitment and
relieving an arrest of NSC differentiation into oligodendro-
cytes. This is in line with previous studies also showing that
increasing the levels of SHH in the brain enhances the
generation of OPCs but blocks their maturation.
Conclusion
Our results with human iPSC show that partial inhib-
ition of GLI1 in hESC-derived NSCs followed by the
activation SHH signaling in NSC differentiation toward
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OPCs leads to earlier maturation of oligodendrocytes in
vitro. Our small molecule-based oligodendrocyte differ-
entiation protocol is faster than all protocols reported so
far. iPSC technology is fast developing as a tool for ex-
ploring new drug targets and gaining mechanistic insight
into neurological disease. Development of iPSC-derived
protocols that lead to efficient and faster differentiation
of oligodendrocytes from neural progenitors provides
important advances toward the development of autolo-
gous neural progenitor cell-based therapies
Additional files
Additional file 1: Figure S1. (A) Cytotoxicity curve of GANT61 in iPSC
(n = 3). Cells were treated with various doses of GANT61 for 5 days.
Cytotoxicity was measured on day 6. (B) Dose-dependent reduction GLI1
mRNA in iPSC by a 5-day treatment with GANT61. (C) SHH pathway gene
expression pattern of undifferentiated hESC, hESC derived-NSCs, and
OLIG2-OPCs (n = 3, t test). (D) The quantification of nestin+, and (E)
SOX2+ NSCs derived from OLIG2-GFP hESCs, show that similar number of
NSCs were generated from both groups (control vs. GANT61).
Immunofluorescence staining was done on day 5 of the differentiation
timeline (n = 3). The percentages were calculated by counting the total
number of DAPI-positive cells and the number of SOX2 or nestin-positive
cells. Error bars indicate SEM. n.s = not significantly different. (TIF 844 kb)
Additional file 2: Figure S2. (A-E) Expression levels of genes in the
SHH pathway in OLIG2/GFP-hiPSC derived OPCs upon the restimulation
with SHH agonist purmorphamine (n = 3). (F, G) The representative flow
cytometry data of the NG2+ population from GANT61-OPCs and control-
OPC and the generation of OLIG2-GFP OPCs (n = 3). (TIF 171 kb)
Additional file 3: Figure S3. The cell viability of (A) OLIG2-NSCs and
(B) OLIG2-OPCs. Only live-cells (propidium iodide negative, right panel)
were selected and analyzed their dividing population based on the
fluorescence dye dilution (n = 3 independent experiments). (TIF 465 kb)
Additional file 4: Figure S4. (A) Control- and GANT61-treated H9
OLIG2-GFP-hESC line-derived oligospheres expressing OLIG2 (green
spheres). OLIG2-GFP-hESC were treated with GANT61 from day 0 to 5.
Spheres were plated on day 24 and early OPCs migrated out within 48 h.
Images are representations of 3 independent experiments. (TIF 6029 kb)
Additional file 5: Figure S5. (A) GANT61-treated hESC gave rise to
functional oligodendrocytes. O4-positive OLs co-cultured with rat DRG
neurons were able to myelinate them (n = 3, images have been taken
from one experiment). MBP (red immune stain) co-labeled with SMI312
(magenta)-labeled neuronal tracts. The OLs were identified with anti-
human nuclei antibody (green stain) which co-labeled with DAPI. (B)
GANT61 treated hESC-derived OPCs were transplanted into the corpus
callosum of the myelin deficient shiverer mouse. After 4 weeks,
transplanted cells were identified with anti-GFP antibody (green) (n = 3).
The MBP-positive cells (red) co-labeled with the GFP-expressing cells
indicating that the OPCs matured into MBP producing oligodendrocytes.
(TIF 2010 kb)
Additional file 6: Table S1. List of primers used in this study.
(DOCX 15 kb)
Additional file 7: Upregulated and downregulated genes. (XLSX5 31
kb)
Additional file 8: GO terms that were found to be significantly
enriched in the GANT61-OPCs. (XLSX 12 kb)
Additional file 9: GO significantly downregulated in GANT61-OPCs. (XLSX
11 kb)
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